Latest Headlines

Latest Headlines

UPDATED: Verastem shares crater on Twitter chatter around cancer data

Shares of Verastem cratered Wednesday morning as the Twitter crowd passed around an abstract on the company's defactinib (VS-6063), highlighting an extremely poor response rate for KRAS mutant non-small cell lung cancer.

Verastem rides rally to snap up $52M in public offering

Like many biotech companies, The Cambridge, MA-based cancer drug developer, whose shares had slumped after its IPO early last year, has seen its share price spike in recent weeks amid mounting interest in the sector from public investors.

Biotech vet Westphal to exit CEO post of cancer drug developer Verastem

Verastem has changed CEOs as the company seeks to translate stem cell discoveries into powerful new cancer drugs. Biotech entrepreneur and Verastem co-founder Christoph Westphal is stepping down from the chief executive post, and president and COO Robert Forrester will take the top job at the company and join the board of directors on July 1.

Verastem gears up for companion Dx mesothelioma treatment trial

Verastem's quest to develop drugs that block cell signaling pathways that cancer stem cells need to survive hits a major milestone in mid-2013, when it launches a 350-patient clinical trial of a potential companion biomarker test for its investigative mesothelioma drug treatment.

LabCorp inks companion diagnostic deal with Verastem

Verastem has signed on with LabCorp to validate biomarkers and develop companion diagnostics for VS-6063, the company's in-development mesothelioma treatment.

In deal flurry, Verastem vaults to PhII on Pfizer cancer drug pact

In a series of rapid-fire press releases over the past 18 hours, cancer drug upstart Verastem vaulted to the threshold of Phase II with an in-licensing deal with Pfizer, announced a development pact with Eisai and ran through a series of highlights for its R&D day review.

OncoMed offers $115M IPO bet on cancer stem cell work

A year after scoring a $20 million milestone from Bayer, OncoMed Pharmaceuticals is preparing to see if it can generate enough excitement from investors for its cancer stem cell work to support a $115 million IPO.

Company 'insiders' left with 43% of Verastem's shares

Anyone trying to understand what it takes to pull off a successful biotech IPO these days should check out a series of 13Ds Verastem's ($VSTM) insiders filed last month. In the days after...

Osteoporosis drug developer Radius Health braves chilly IPO market

After burning through more than $122 million, the late-stage osteoporosis drug developer Radius Health is filing to go public in the hope of raising up to $86 million. Radius is betting that it can

Westphal pulls off a rare stunt with $55M Verastem IPO

Christoph Westphal's Verastem, a preclinical-stage biotech focused on cancer stem cell research, seemingly defied gravity with an announcement late last night that its IPO raised $55 million from the